Effect of cancer/testis antigen NY‑SAR‑35 on the proliferation, migration and invasion of cancer cells

Song,Myung‑Ha; Kim,Ye‑Rin; Bae,Jae‑Ho; Lee,Chang‑Hun; Lee,Sang‑Yull

doi:10.3892/ol.2016.5498

Effect of cancer/testis antigen NY‑SAR‑35 on the proliferation, migration and invasion of cancer cells

Authors:
- Myung‑Ha Song
- Ye‑Rin Kim
- Jae‑Ho Bae
- Chang‑Hun Lee
- Sang‑Yull Lee
View Affiliations

Affiliations: Department of Biochemistry, School of Medicine, Pusan National University, Yangsan, Gyeongsangnam‑do 626‑870, Republic of Korea, Department of Pathology, School of Medicine, Pusan National University, Yangsan, Gyeongsangnam‑do 626‑870, Republic of Korea
Published online on: December 14, 2016 https://doi.org/10.3892/ol.2016.5498
Pages: 784-790
Copyright: © Song et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

NY-SAR-35 is a cancer/testis (CT) antigen that was identified by serological analysis of recombinant complementary DNA expression libraries. The gene encoding NY‑SAR‑35 is located on the X chromosome and is aberrantly expressed in a number of cancer types and germ cells, such as those in the testes, but not in normal tissue. It has been reported that treatment with a demethylating agent induced the expression of NY‑SAR‑35 in several types of cancer cells. However, the function of NY‑SAR‑35 in cancer remains undetermined. In present study, the role of NY‑SAR‑35 in human lung adenocarcinoma (SK‑LC‑14) and hepatocellular carcinoma (SNU‑449) cells was investigated following stable transfection of the NY‑SAR‑35 gene. NY‑SAR‑35 was observed to be expressed in the cytoplasm of the cells. In addition, the bromodeoxyuridine incorporation assay and immunofluorescence staining for proliferating cell nuclear antigen and Ki‑67 demonstrated that proliferation was increased in cells transfected with NY‑SAR‑35. In addition, the trypan blue exclusion assay indicated that NY‑SAR‑35 increased cancer cell viability. Furthermore, NY‑SAR‑35 increased the migration and invasion of the cells. These results indicate that NY‑SAR‑35 increases cancer cell viability, proliferation, migration and invasion.

View Figures

View References

1	Scanlan MJ, Simpson AJ and Old LJ: The cancer/testis genes: Review, standardization, and commentary. Cancer Immun. 4:12004.PubMed/NCBI
2	Fratta E, Coral S, Covre A, Parisi G, Colizzi F, Danielli R, Nicolay HJ, Sigalotti L and Maio M: The biology of cancer testis antigens: Putative function, regulation and therapeutic potential. Mol Oncol. 5:164–182. 2011. View Article : Google Scholar : PubMed/NCBI
3	Scanlan MJ, Gure AO, Jungbluth AA, Old LJ and Chen YT: Cancer/testis antigens: An expanding family of targets for cancer immunotherapy. Immunol Rev. 188:22–32. 2002. View Article : Google Scholar : PubMed/NCBI
4	Hofmann O, Caballero OL, Stevenson BJ, Chen YT, Cohen T, Chua R, Maher CA, Panji S, Schaefer U, Kruger A, et al: Genome-wide analysis of cancer/testis gene expression. Proc Natl Acad Sci USA. 105:20422–20427. 2008. View Article : Google Scholar : PubMed/NCBI
5	Simpson AJ, Caballero OL, Jungbluth A, Chen YT and Old LJ: Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer. 5:615–625. 2005. View Article : Google Scholar : PubMed/NCBI
6	Cheng YH, Wong EW and Cheng CY: Cancer/testis (CT) antigens, carcinogenesis and spermatogenesis. Spermatogenesis. 1:209–220. 2011. View Article : Google Scholar : PubMed/NCBI
7	Kulkarni P, Shiraishi T, Rajagopalan K, Kim R, Mooney SM and Getzenberg RH: Cancer/testis antigens and urological malignancies. Nat Rev Urol. 9:386–396. 2012. View Article : Google Scholar : PubMed/NCBI
8	Whitehurst AW: Cause and consequence of cancer/testis antigen activation in cancer. Annu Rev Pharmacol Toxicol. 54:251–272. 2014. View Article : Google Scholar : PubMed/NCBI
9	Lee SY, Obata Y, Yoshida M, Stockert E, Williamson B, Jungbluth AA, Chen YT, Old LJ and Scanlan MJ: Immunomic analysis of human sarcoma. Proc Natl Acad Sci USA. 100:2651–2656. 2003. View Article : Google Scholar : PubMed/NCBI
10	Thim L: Trefoil peptides: From structure to function. Cell Mol Life Sci. 53:888–903. 1997. View Article : Google Scholar : PubMed/NCBI
11	Sands BE and Podolsky DK: The trefoil peptide family. Annu Rev Physiol. 58:253–273. 1996. View Article : Google Scholar : PubMed/NCBI
12	Braun BC, Ringleb J, Waurich R, Viertel D and Jewgenow K: Functional role of feline zona pellucida protein 4 trefoil domain: A sperm receptor or structural component of the domestic cat zona pellucida? Reprod Domest Anim. 44:(Suppl 2). S234–S238. 2009. View Article : Google Scholar
13	Park JH, Song MH, Lee CH, Lee MK, Park YM, Old L and Lee SY: Expression of the human cancer/testis antigen NY-SAR-35 is activated by CpG island hypomethylation. Biotechnol Lett. 33:1085–1091. 2011. View Article : Google Scholar : PubMed/NCBI
14	Davis GL, Dempster J, Meler JD, Orr DW, Walberg MW, Brown B, Berger BD, O'Connor JK and Goldstein RM: Hepatocellular carcinoma: Management of an increasingly common problem. Proc (Bayl Univ Med Cent). 21:266–280. 2008.PubMed/NCBI
15	Yoon SK and Chun HG: Status of hepatocellular carcinoma in South Korea. Chin Clin Oncol. 2:392013.PubMed/NCBI
16	Bae JM, Lee MS, Shin MH, Kim DH, Li ZM and Ahn YO: Cigarette smoking and risk of lung cancer in Korean men: The Seoul male cancer cohort study. J Korean Med Sci. 22:508–512. 2007. View Article : Google Scholar : PubMed/NCBI
17	Jung KW, Won YJ, Kong HJ, Oh CM, Seo HG and Lee JS: Cancer statistics in Korea: Incidence, mortality, survival and prevalence in 2010. Cancer Res Treat. 45:1–14. 2013. View Article : Google Scholar : PubMed/NCBI
18	Chen YT, Hsu M, Lee P, Shin SJ, MhawechFauceglia P, Odunsi K, Altorki NK, Song CJ, Jin BQ, Simpson AJ and Old LJ: Cancer/testis antigen CT45: Analysis of mRNA and protein expression in human cancer. Int J Cancer. 124:2893–2898. 2009. View Article : Google Scholar : PubMed/NCBI
19	Gure AO, Chua R, Williamson B, Gonen M, Ferrera CA, Gnjatic S, Ritter G, Simpson AJ, Chen YT, Old LJ and Altorki NK: Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res. 11:8055–8062. 2005. View Article : Google Scholar : PubMed/NCBI
20	Peng JR, Chen HS, Mou DC, Cao J, Cong X, Qin LL, Wei L, Leng XS, Wang Y and Chen WF: Expression of cancer/testis (CT) antigens in Chinese hepatocellular carcinoma and its correlation with clinical parameters. Cancer Lett. 219:223–232. 2005. View Article : Google Scholar : PubMed/NCBI
21	Nakagawa K, Noguchi Y, Uenaka A, Sato S, Okumura H, Tanaka M, Shimono M, Ali Eldib AM, Ono T, Ohara N, et al: XAGE-1 expression in non-small cell lung cancer and antibody response in patients. Clin Cancer Res. 11:5496–5503. 2005. View Article : Google Scholar : PubMed/NCBI
22	Kurashige T, Noguchi Y, Saika T, Ono T, Nagata Y, Jungbluth A, Ritter G, Chen YT, Stockert E, Tsushima T, et al: Ny-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: Correlation with tumor grade. Cancer Res. 61:4671–4674. 2001.PubMed/NCBI
23	Scanlan MJ, Altorki NK, Gure AO, Williamson B, Jungbluth A, Chen YT and Old LJ: Expression of cancer-testis antigens in lung cancer: Definition of bromodomain testis-specific gene (BRDT) as a new CT gene, CT9. Cancer Lett. 150:155–164. 2000. View Article : Google Scholar : PubMed/NCBI
24	Ayyoub M, Taub RN, Keohan ML, Hesdorffer M, Metthez G, Memeo L, Mansukhani M, Hibshoosh H, Hesdorffer CS and Valmori D: The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma. Cancer Immun. 4:72004.PubMed/NCBI
25	Dobrynin P, Matyunina E, Malov SV and Kozlov AP: The novelty of human cancer/testis antigen encoding genes in evolution. Int J Genomics. 2013:1051082013. View Article : Google Scholar : PubMed/NCBI
26	Pandey A, Kurup A, Shrivastava A, Radhi S, Nguyen DD, Arentz C, D'Chuna N, Hardwick F, D'Souza MJ, Jenkins M, et al: Cancer testes antigens in breast cancer: Biological role, regulation, and therapeutic applicability. Int Rev Immunol. 31:302–320. 2012. View Article : Google Scholar : PubMed/NCBI
27	Shiraishi T, Terada N, Zeng Y, Suyama T, Luo J, Trock B, Kulkarni P and Getzenberg RH: Cancer/testis antigens as potential predictors of biochemical recurrence of prostate cancer following radical prostatectomy. J Transl Med. 9:1532011. View Article : Google Scholar : PubMed/NCBI
28	Kelman Z: PCNA: Structure, functions and interactions. Oncogene. 14:629–640. 1997. View Article : Google Scholar : PubMed/NCBI
29	Gerdes J, Schwab U, Lemke H and Stein H: Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 31:13–20. 1983. View Article : Google Scholar : PubMed/NCBI
30	Ihmann T, Liu J, Schwabe W, Häusler P, Behnke D, Bruch HP, Broll R, Windhovel U and Duchrow M: High-level mRNA quantification of proliferation marker pKi-67 is correlated with favorable prognosis in colorectal carcinoma. J Cancer Res Clin Oncol. 130:749–756. 2004. View Article : Google Scholar : PubMed/NCBI
31	Bologna-Molina R, MosquedaTaylor A, MolinaFrechero N, MoriEstevez AD and Sánchez-Acuña G: Comparison of the value of PCNA and Ki-67 as markers of cell proliferation in ameloblastic tumors. Med Oral Patol Oral Cir Bucal. 1:e174–e179. 2013. View Article : Google Scholar
32	Song MH, Kim YR, Lee JW, Lee CH and Lee SY: Cancer/testis antigen NY-SAR-35 enhances cell proliferation, migration and invasion. Int J Oncol. 48:569–576. 2016.PubMed/NCBI